Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 4, 2005 - Issue 3
Submit an article Journal homepage
24
Views
1
CrossRef citations to date
0
Altmetric
Review

Are rates of gastrointestinal bleeding higher following the introduction of COX-2 inhibitors?

Muhammad MamdaniInstitute for Clinical Evaluative Sciences 2075 Bayview Avenue – G215, Toronto, OntarioCanadaTel: +1 416 4804055; Fax: +1 416 4806048;E-mail: [email protected]
Pages 591-598 | Published online: 10 May 2005

Bibliography

  • BARAT I, ANDREASEN F, DAMSGAARD EMS: The consumption of drugs by 75-year-old individuals living in their own homes. Eur. Clin. Pharmacol (2000) 56:501–509.
  • LAZZARONI M, BIANCHI PORRO G: Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment. Pharmacol Ther. (2004) 20\(Suppl. 2):48–58.
  • PAULUS HE. FDA Arthritis Advisory Committee meeting: serious gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum. (1988) 31:1450–1451.
  • FELDMAN M, MCMAHON AT: Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med. (2000) 132:134–143.
  • HAWKEY CJ: COX-2 inhibitors. Lancet (1999) 353:307–14.
  • ••An excellent review of COX-2 inhibitors.
  • BOMBARDIER C, LAINE L, REICIN Aet al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. I. Med. (2000) 343:1520–1528.
  • •This article represents a pivotal COX-2 Inhibitor trial suggesting GI safety of a COX-2 inhibitor (rofecoxib) relative to nonselective NSAIDs.
  • SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA (2000) 284:1247–1255.
  • •Another trial which suggests GI safety of a COX-2 inhibitor (celecoxib) In realtion to nonselective NSAIDS.
  • SCHNITZER TJ, BURMESTER GR, MYSLER E et al: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet (2004) 364:665–674.
  • •Another trial which suggests GI safety of a COX-2 inhibitor (lumiracoxib) in realtion to nonselective NSAIDS.
  • MAMDANI M, ROCHON P, JUURLINK DN et al: Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BE Med. J. (2002) 325:624–627.
  • MACDONALD TM, MORANT SV, GOLDSTEIN JL, BURKE TA, PETTITT D: Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut (2003) 52:1265–1270.
  • IMS Health Canada Newsletter September 1999.
  • WRIGHT JM, PERRY TL, BASSETT KL, CHAMBERS GK: Reporting of 6-month versus 12-month data in a clinical trial of celecoxib. JAMA (2001) 286:2398–2400.
  • SILVERSTEIN F, SIMON L, FAICH G: Reporting of 6-month versus 12-month data in a clinical trial of celecoxib. In reply. JAMA (2001) 286:2399–2400
  • SINGH G, LANES S, TRIADAFILOPOULOS G: Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am. J. Med. (2004) 117:100–106.
  • CURTIS SP, LEE M, NG J et al: Fewer upper-GI perforations, ulcers, and bleeds (PUBs) with etoricoxib than with non-selective cyclooxygenase inhibitors (NSAIDs). Ann. Rheum. Dis. (2002) 61:177.
  • GOLDSTEIN JL, KIVITZ AJ, VERBURG KM, RECKER DP, PALMER RC, Kent JD: A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment. Pharmacol Ther. (2003) 18:125–132.
  • HUNT RH, HARPERS, WATSON DJ et al: The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am. Castroenterol (2003) 98:1725–1733.
  • HENRY D, LIM LL, GARCIA RODRIGUEZ LA et al: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BE Med. J. (1996) 312:1563–1566.
  • JUNI P, RUTJES AWS, DIEPPE PA: Are the COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Br. Med. J. (2002) 324:1287–1288.
  • WARNER TD, GIULIANO F, VOJNOVIC I, BUKASA A, MITCHELL JA, VANE JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Nati Acad. Sci. USA (1999) 96:7563–7568.
  • BLAIN H, BOILEAU C, LAPICQUE F et al: Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br. J. Chi]. Pharmacol (2002) 53:255–265.
  • HAWK ET, VINER JL, DANNENBERG A, DUBOIS RN: COX-2 in cancer - a player that's defining the rules. I Natl Cancer Inst. (2002) 94:545–546.
  • PATTI R, GUMIRED K, REDDANNA P, SUTTON LN, PHILLIPS PC, REDDY CD: Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib. Cancer Lett. (2002) 180(1):13–21.
  • WASKEWICH C, BLUMENTHAL RD, LI H, STEIN R, GOLDENBERG DM, BURTON J: Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. (2002) 62:2029–2033.
  • BOUEE S, CHARLEMAGNE A, FAGNANI F et al: Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. Joint Bone Spine (2004) 71:214–220.
  • LELORIER J, FITZSIMON C, KERESTECI M, STEWART D, LAVOIE F: Drug utilization review of celecoxib in Ontario. Rheumatology (Oxford) (2003) 42 (Suppl. 3) :iiill-iii16.
  • CHAN FK, HUNG LC, SUEN BY et al: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl. J. Med. (2002) 347:2104–2110.
  • SPIEGEL BM, TARGOWNIK L, DULAI GS, GRALNEK IM: The cost effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann. Intern. Med. (2003) 138:795–806.
  • MORIDE Y, DUCRUET T, ROCHON S, LAVOIE F: Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Rheumatology (Oxford) (2003) 42\(Supp1.3):iii17-iii22.
  • ROTHMAN KJ, GREENLAND S: Modern epidemiology. Boston: Lippincott-Raven, 1998.
  • NORGARD B, PEDERSEN L, JOHNSEN SP et al: COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Ailment. Pharmacol Ther. (2004) 19:817–825.
  • LAPORTE JR, IBANEZ L, VIDAL X, VENDRELL L, LEONE R: Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Sal: (2004) 27:411–420.
  • RUBIN DB: Estimating causal effects from large data sets using propensity scores. Ann. Intern. Med. (1997) 127:757–763.
  • BENSON K, HARTZ AJ: A comparison of observational studies and randomized, controlled trials. N Engl. I Med. (2000) 342:1878–1886.
  • GIRVIN B, RAFFERTY T, STEVENSON MR, JOHNSTON GD: Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland. Pharmacoepidemiol Drug Sal (2004) 13:153–157.
  • MAMDANI M, ROCHON P, LAUPACIS A, ANDERSON G: Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. CMAJ(2002) 167:1125–1126.
  • HAWKEY CJ: COX-1 and COX-2 inhibitors. Best Pract. Res. OM Castroenterol (2001) 15:801–820.
  • MAMDANI M, JUURLINK DN, KOPP A, NAGLIE G, AUSTIN PC, LAUPACIS A: Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. Br. Med. J. (2004) 328:1415–1416.
  • ••The original study demonstrating anincrease in population rates of GI bleeding rates following the introduction of COX-2 inhibitors.
  • WEBER A, CASINI A, HEINE A et al: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. (2004) 47:550–557.
  • SUPURAN CT, CASINI A, MASTROLORENZO A, SCOZZAFAVA A: COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini Rev Med. Chem. (2004) 4:625–632.
  • PUSCAS I, COLTAU M, PASCA R: Nonsteroidal anti-inflammatory drugs activate carbonic anhydrase by a direct mechanism of action. J. Pharmacol Exp. Ther. (1996) 277:1464–1466.
  • PUSCAS I: Treatment of gastroduodenalulcers with carbonic anhydrase inhibitors. Ann. NY Acad. Sci. (1984) 429:426–431.
  • PUSCAS I, COLTAU M, BAICAN M, PASCA R, DOMUTA G, HECHT A: Vasoconstrictive drugs increase carbonic anhydrase I in vascular smooth muscle while vasodilating drugs reduce the activity of this isozyme by a direct mechanism of action. Drugs Exp. Clin. Res. (2001) 27:53–60.
  • TOPOL EJ: Arthritis medicines and cardiovascular events - 'house of coxibs'. JAMA (2005) 293:366–368.

Websites

  • http://www.aihw.gov.au/publications/ health/mhhcdgpa/index.html. SAYER GP, BRITT H, HORN F et al.: Measures of Health and Health Care Delivery in General Practice in Australia. Australian Institute of Health and Welfare (2000).
  • www.fda.gov/ohrms/dockets/ac/01/ briefing/3677b1_04_stats.doc. FDA website report. LU HL: Statistical reviewer briefing document for the advisory committee.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.